SCHEMBL9952434

SCHEMBL9952434

Cc1ccc(CC(N)C(=O)O)cc1O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 8/20 0.73
USP2 O75604 3/20 0.73
PTGS1 P23219 2/20 0.73
KDM4E B2RXH2 2/20 0.73
ALOX15 P16050 2/20 0.73
RECQL P46063 2/20 0.73
HIF1A Q16665 2/20 0.73
HSD17B10 Q99714 2/20 0.73
TDP1 Q9NUW8 2/20 0.73
EGFR P00533 1/20 0.73
LCK P06239 1/20 0.73
FYN P06241 1/20 0.73
ADORA3 P0DMS8 1/20 0.73
HTR2A P28223 1/20 0.73
PTGS2 P35354 1/20 0.73
THRB P10828 4/20 0.54
THRA P10827 3/20 0.54
PKM P14618 3/20 0.53
ALPI P09923 1/20 0.53
XIAP P98170 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9952430 1.00 SLC7A5 (0.73) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL20921848 0.88 ALOX15 (0.56) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL31263758 0.87 SLC7A5 (0.73) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL274387 0.87 SLC7A5 (0.73) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL274388 0.87 SLC7A5 (0.73) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL6154805 0.87 SLC7A5 (0.73) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL2778612 0.86 SLC7A5 (0.62) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL31734663 0.86 SLC7A5 (0.62) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL31734665 0.86 SLC7A5 (0.62) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL31734671 0.86 SLC7A5 (0.62) SLC7A5USP2PTGS1KDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107090476-B Sanglifehrin derivatives and process for preparing the same 爱博利瓦有限公司 2021-09-24 CN disclosed
EP-3427737-A1 SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION NeuroVive Pharmaceutical AB (SE) 2019-01-16 EP disclosed
EP-2654753-B1 SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION NEUROVIVE PHARMACEUTICAL AB (SE) 2018-10-31 EP disclosed
US-9867845-B2 Vectors for delivery of agents across biological membranes THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-01-16 US disclosed
EP-2770977-B1 NOVEL DOSAGE FORM NEUROVIVE PHARMACEUTICAL AB (SE) 2017-07-12 EP disclosed
US-9504728-B2 Dosage form NEUROVIVE PHARMACEUTICAL AB (SE) 2016-11-29 US disclosed
US-9271977-B2 Sanglifehrin derivatives and methods for their production NEUROVIVE PHARMACEUTICAL AB (SE) 2016-03-01 US disclosed
US-9139613-B2 Macrocyclic compounds and methods for their production NEUROVIVE PHARMACEUTICAL AB (SE) 2015-09-22 US disclosed
EP-2691413-B1 MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION NEUROVIVE PHARMACEUTICAL AB (SE) 2014-12-24 EP disclosed
US-8901295-B2 Inhibitors of cyclophilins and uses thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-12-02 US disclosed
US-8802666-B2 Inhibitors of cyclophilins and uses thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-08-12 US disclosed
US-20140179687-A1 New Inhibitors of Cyclophilins and Uses Thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-06-26 US disclosed
US-20140080837-A1 Sanglifehrin Derivatives and Methods for Their Production Neurovive Pharmaceuticals AB (SE) 2014-03-20 US disclosed
US-20140038885-A1 Macrocyclic Compounds and Methods for Their Production NEUROVIVE PHARMACEUTICAL AB (SE) 2014-02-06 US disclosed
EP-2691413-A1 MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION Neurovive Pharmaceutical AB (SE) 2014-02-05 EP disclosed
EP-2654753-A1 SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION Neurovive Pharmaceutical AB (SE) 2013-10-30 EP disclosed
WO-2013061052-A1 NOVEL DOSAGE FORM BIOTICA TECHNOLOGY LIMITED (GB) 2013-05-02 WO disclosed
US-20130018044-A1 NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2013-01-17 US disclosed
WO-2012131377-A1 MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION BIOTICA TECHNOLOGY LIMITED (GB) 2012-10-04 WO disclosed
WO-2012085553-A1 SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION BIOTICA TECHNOLOGY LIMITED (GB) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179687-A1 New Inhibitors of Cyclophilins and Uses Thereof FKBP3, FKBP4, FKBP5 SLC7A5 1467/4885USP2 2824/4885PTGS1 1125/4885
US-20140080837-A1 Sanglifehrin Derivatives and Methods for Their Production MAVS, HDGF, TTPA SLC7A5 4617/4885USP2 4295/4885PTGS1 459/4885
US-20140038885-A1 Macrocyclic Compounds and Methods for Their Production HAVCR2, RPL35, CD4 SLC7A5 1425/4885USP2 4542/4885PTGS1 1385/4885
US-20130018044-A1 NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF FKBP3, FKBP4, FKBP5 SLC7A5 1467/4885USP2 2824/4885PTGS1 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.